Drug Type Bispecific antibody |
Synonyms Anti-PDL1/TGF-bifunctional fusion protein - Shandong Boan Biotechnology + [1] |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal Neoplasms | Phase 1 | CN | 31 Oct 2022 | |
Non-Small Cell Lung Cancer | Phase 1 | CN | 31 Oct 2022 | |
Small Cell Lung Cancer | Phase 1 | CN | 31 Oct 2022 | |
Transitional Cell Carcinoma | Phase 1 | CN | 31 Oct 2022 | |
Uterine Cervical Cancer | Phase 1 | CN | 31 Oct 2022 | |
Small Cell Carcinoma | Phase 1 | CN | 18 Jul 2022 | |
malignant carcinoid tumor of digestive tract | Phase 1 | CN | - | |
Uterine Corpus Cancer | Phase 1 | CN | - |